Roth Capital Maintains a Buy Rating on Trinity Biotech Plc

By George MacDonald

In a report released today, Chris Lewis from Roth Capital maintained a Buy rating on Trinity Biotech Plc (NASDAQ: TRIB), with a price target of $22. The company’s shares opened today at $18.06.

Lewis said, “We recently met with TRIB management at ROTH’s 2 nd annual Healthcare Access Day in London. Importantly, it appears TRIB’s U.S. troponin clinical trial remains on track and we expect enrollment completion should occur next month (July). On the M&A front, management communicated it remains active in its search for synergistic opportunities, however, nothing appears imminent as of now. We maintain our Buy rating and raise our target to $22, from $21, to reflect our upwardly revised troponin NPV calculation. Troponin U.S. Trial Update: We believe TRIB’s U.S.”

Trinity Biotech Plc has an analyst consensus of Hold.

The company has a one year high of $23.71 and a one year low of $13.83. Currently, Trinity Biotech Plc has an average volume of 107.9k.

According to TipRanks.com, Lewis is a 4-star analyst with an average return of 12.2% and a 61.7% success rate. Lewis covers the Healthcare sector, focusing on stocks such as Natus Medical Inc., Enteromedics Inc., and Lemaitre Vascular.

Trinity Biotech PLC develops, acquires, manufactures & markets medical diagnostic products for clinical laboratory & point-of-care of diagnostic market. Its products are used to detect autoimmune, infectious, diabetes and disorders of liver & intestine.